Lilly allocates additional US $50 million to Social Impact Venture Capital portfolio

The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries

USFDA approves GSK’s respiratory syncytial virus vaccine ‘Arexvy’

Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time

Ascentage presents results of studies underscoring exploratory efforts in potential

The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications

Agilent showcases cancer portfolio Solutions at AACR 2023

From cancer research to diagnostic solutions

Alpenglow Biosciences and Mayo Clinic collaborate to advance pathology and drug development through 3D spatial biology

Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

CTSI appoints Harish Trivedi as CEO, South Asia

Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata

The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022

Precision appoints John Hubbard, PhD, as Board of Directors Chair

Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.

Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.